摘要
目的探讨血清肿瘤因子鳞状细胞癌相关抗原(SCCA)和血清蛋白类标记物铁蛋白联合检测对宫颈癌的诊断价值及临床意义。方法 83例宫颈癌患者、35例宫颈良性肿瘤患者及45名健康人进行血清SCCA和铁蛋白水平检测,比较3组血清SCCA和铁蛋白表达差异及不同病理类型宫颈癌患者血清SCCA和铁蛋白表达差异。结果宫颈癌患者血清SCCA和铁蛋白水平分别为(5.36±0.89)μg/L和(278.6±16.63)μg/L,高于健康人[(0.86±0.12)μg/L和(39.6±5.75)μg/L]及宫颈良性肿瘤患者[(0.96±0.39)μg/L和(48.6±9.63)μg/L],差异有统计学意义(P<0.05);健康人及宫颈良性肿瘤患者之间表达差异无统计学意义(P>0.05)。结论 SCCA和铁蛋白在宫颈癌患者血清表达有不同程度差异,对其联合检测有助于宫颈癌的诊断及分型。
Objective To explore diagnostic value of joint test of serum tumor factors related to squamous cell carcinoma（SCCA） and related antigen serum protein markers of iron protein（ferroprotein） the in cervical cancer. Methods 83 cases with cervical cancer,35 cases with cervical benign tumor and 45 healthy cases were detected for SCCA and ferroprotein level. Serum SCCA and ferroprotein expression differences in three groups were analyzed and compared. Results Serum SCCA and ferroprotein level in cervical cancer patients were（S. 36±0.89）μg/L, （278.6± 16.63）μg/L, these were higher than normal cases[-（0. 86 ± 0. 12） μg/L, （39. 6±5. 75）μg/L] and cervical benign tumor cases[（0.96±0.39）tLg/L, （48.6±9.63）μg/L]. Expressions of these were not significantly different between normal cases and cervical benign tumor cases. Conclusion SCCA and ferroprotein in cervical cancer patients have expression differences, the joint test can help to diagnose cervical cancer.
出处
《检验医学与临床》
CAS
2012年第18期2279-2280,共2页
Laboratory Medicine and Clinic
关键词
宫颈癌
鳞状细胞癌抗原
铁蛋白
肿瘤患者
cervical carcinoma
squamous cell carcinoma-related
antigen ferroprotein
tumor patients
